Altre lingue Vaxcyte, Inc.

Azioni

PCVX

US92243G1085

Tempo reale stimato Cboe BZX Altri mercati azionari 21:47:29 09/07/2024			Variaz. 5gg	Var. 1 gen.
80,78 ^USD	+1,80%		+6,39%	+28,85%

02/07	Vaxcyte, Inc. nomina John P. Furey come membro del Comitato per le remunerazioni	CI
02/07	Vaxcyte nomina John Furey nel Consiglio di Amministrazione	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Vaxcyte, Inc. Appoints John P. Furey as Member of the Compensation Committee	02/07
Vaxcyte Appoints John Furey to Board of Directors	02/07
Vaxcyte Appoints John Furey to Board of Directors	02/07
Vaxcyte Insider Sold Shares Worth $599,909, According to a Recent SEC Filing	22/05
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update	08/05
Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	25/04
Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	22/04
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Certain Pre-Funded Warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31/03
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing	21/03
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants	04/03
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	04/03
Vaxcyte Q4 Loss Widens	27/02
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	27/02
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024	15/02
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	03/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Vaxcyte, Inc.

Azioni

PCVX

US92243G1085

Altre lingue

Filtri